Alkermes (ALKS) Expected to Announce Earnings on Tuesday

28 Apr 2026, 13:18 by Renee Jackson · The Cerbat Gem

Alkermes (NASDAQ:ALKS – Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Alkermes to post earnings of ($0.57) per share and revenue of $362.7780 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:00 AM ET.

Alkermes (NASDAQ:ALKS – Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported $0.29 EPS for the quarter. The firm had revenue of $384.55 million during the quarter. Alkermes had a return on equity of 14.91% and a net margin of 16.37%. On average, analysts expect Alkermes to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Trading Up 1.0%

Shares of NASDAQ:ALKS traded up $0.35 during trading on Tuesday, hitting $34.08. 719,910 shares of the company were exchanged, compared to its average volume of 2,236,039. Alkermes has a fifty-two week low of $25.17 and a fifty-two week high of $36.48. The stock has a market cap of $5.67 billion, a price-to-earnings ratio of 23.85 and a beta of 0.44. The firm has a fifty day moving average price of $31.35 and a two-hundred day moving average price of $30.90.

Insider Transactions at Alkermes

In other news, EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $34.57, for a total value of $70,315.38. Following the transaction, the executive vice president owned 233,592 shares of the company’s stock, valued at approximately $8,075,275.44. This represents a 0.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Shane Cooke sold 61,200 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the transaction, the director owned 103,744 shares in the company, valued at approximately $3,586,430.08. This trade represents a 37.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 159,468 shares of company stock worth $5,433,699. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Alkermes

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada boosted its position in shares of Alkermes by 117.2% in the first quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock valued at $9,098,000 after acquiring an additional 148,696 shares during the period. Ashton Thomas Private Wealth LLC bought a new position in Alkermes during the first quarter worth about $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Alkermes by 4.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock worth $15,927,000 after purchasing an additional 20,091 shares in the last quarter. Cetera Investment Advisers raised its stake in Alkermes by 32.3% in the 2nd quarter. Cetera Investment Advisers now owns 13,907 shares of the company’s stock worth $398,000 after purchasing an additional 3,394 shares in the last quarter. Finally, Quantbot Technologies LP boosted its holdings in Alkermes by 539.4% in the 2nd quarter. Quantbot Technologies LP now owns 6,976 shares of the company’s stock valued at $200,000 after purchasing an additional 5,885 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

Analyst Upgrades and Downgrades

ALKS has been the topic of several research analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Alkermes in a research note on Monday, December 29th. Wall Street Zen downgraded Alkermes from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Bank of America increased their price target on Alkermes from $34.00 to $36.00 and gave the company a “neutral” rating in a research note on Thursday, April 9th. Zacks Research downgraded Alkermes from a “hold” rating to a “strong sell” rating in a report on Friday, March 20th. Finally, Piper Sandler decreased their price objective on shares of Alkermes from $45.00 to $43.00 and set an “overweight” rating on the stock in a report on Tuesday, March 24th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Alkermes presently has an average rating of “Moderate Buy” and a consensus target price of $44.07.

View Our Latest Stock Report on ALKS

Alkermes Company Profile

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.